Literature DB >> 16985855

Evaluating men with benign prostatic hyperplasia.

Herbert Lepor.   

Abstract

The clinical manifestations of benign prostatic hyperplasia (BPH) include lower urinary tract symptoms (LUTS), poor bladder emptying, urinary retention, detrusor instability, urinary tract infection, hematuria, and renal insufficiency. However, the majority of men with BPH present with LUTS only. Because LUTS can indicate a variety of conditions, evaluation of symptomatic men must first aim to identify or exclude BPH and, if present, assess its severity. It is important to assess symptom severity at baseline and during follow-up, using the American Urological Association Symptom Index or the International Prostate Symptom Score. Further testing can then be tailored to narrow the diagnosis and guide treatment decisions. Factors such as patient age and concomitant malignancy will also affect management, but the main goal of treatment remains the improvement of quality of life for the patient.

Entities:  

Year:  2004        PMID: 16985855      PMCID: PMC1472850     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  26 in total

1.  Radical retropubic prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms.

Authors:  E J Schwartz; H Lepor
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

2.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

3.  Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.

Authors:  M J Barry; A T Cockett; H L Holtgrewe; J D McConnell; S A Sihelnik; H N Winfield
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

4.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Authors:  C G Roehrborn; P Boyle; A L Gould; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

5.  Value of postvoid residual urine determination in evaluation of prostatism.

Authors:  R C Bruskewitz; P Iversen; P O Madsen
Journal:  Urology       Date:  1982-12       Impact factor: 2.649

6.  Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia.

Authors:  G Bartsch; H R Müller; M Oberholzer; H P Rohr
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

7.  Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound.

Authors:  C G Roehrborn; C J Girman; T Rhodes; K A Hanson; G N Collins; S M Sech; S J Jacobsen; W M Garraway; M M Lieber
Journal:  Urology       Date:  1997-04       Impact factor: 2.649

8.  Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.

Authors:  J D McConnell; M J Barry; R C Bruskewitz
Journal:  Clin Pract Guidel Quick Ref Guide Clin       Date:  1994-02

9.  Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia.

Authors:  P F Rosier; J J de la Rosette; E L Koldewijn; F M Debruyne; H Wijkstra
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450

10.  The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

Authors:  H Lepor; W O Williford; M J Barry; C Haakenson; K Jones
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more
  9 in total

1.  A prospective video-controlled study of genito-urinary disorders in 35 consecutive laparoscopic TMEs for rectal cancer.

Authors:  Andrea Costanzi; Luca Rigamonti; Giulio Maria Mari; Angelo Miranda; Jacopo Crippa; Valter Berardi; Dario Maggioni
Journal:  Surg Endosc       Date:  2014-10-11       Impact factor: 4.584

2.  Effect of Metabolic Syndrome on Anatomy and Function of the Lower Urinary Tract Assessed on MRI.

Authors:  Alex P Tannenbaum; Matthew D Grimes; Christopher L Brace; Cody J Johnson; Samuel D Koebe; Lucille E Anzia; Lu Mao; William A Ricke; Diego Hernando; Alejandro Roldan-Alzate; Shane A Wells
Journal:  Urology       Date:  2021-09-24       Impact factor: 2.633

3.  Comparison between visual prostate symptom score and international prostate symptom score in males older than 40 years in rural Indonesia.

Authors:  Andika Afriansyah; Yogi Ismail Gani; Hari Nusali
Journal:  Prostate Int       Date:  2014-08-21

4.  Development of Decision Support Formulas for the Prediction of Bladder Outlet Obstruction and Prostatic Surgery in Patients With Lower Urinary Tract Symptom/Benign Prostatic Hyperplasia: Part I, Development of the Formula and its Internal Validation.

Authors:  Min Soo Choo; Changwon Yoo; Sung Yong Cho; Seong Jin Jeong; Chang Wook Jeong; Ja Hyeon Ku; Seung-June Oh
Journal:  Int Neurourol J       Date:  2017-04-21       Impact factor: 2.835

5.  Risk Factors for Prostate Volume Progression After Prostate-Transurethral Resection.

Authors:  Gede Wirya Kusuma Duarsa; Daniel Oktavianus Dau; Ida Bagus Putra Pramana; Pande Made Wisnu Tirtayasa; I Wayan Yudiana; Kadek Budi Santosa; Anak Agung Gde Oka; Tjokorda Gde Bagus Mahadewa; Christopher Ryalino
Journal:  Res Rep Urol       Date:  2020-05-05

6.  Assessment of posterior urethra in benign prostatic hyperplasia and after its surgery.

Authors:  Vivek Agrawal; Rahul Khullar; Ashesh Kumar Jha
Journal:  Urol Ann       Date:  2020-01-13

7.  Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.

Authors:  Ferdinando Fusco; Gianluca D'Anzeo; Carsten Henneges; Andrea Rossi; Hartwig Büttner; J Curtis Nickel
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

8.  Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.

Authors:  Michael A Kiebish; Poornima Tekumalla; Shobha Ravipaty; Albert Dobi; Shiv Srivastava; Wenfang Wu; Saurabh Patil; Tracey Friss; Allison Klotz; Alagarsamy Srinivasan; Jennifer Cullen; Inger L Rosner; Amina Ali; Sandra Laszlo; Michele Petrovic; Neil Fleshner; Jeonifer Garren; Greg Miller; Nischal Mahaveer Chand; Leonardo O Rodrigues; Elder Granger; Mark D Kellogg; Shen Luan; Eleftherios Diamandis; Viatcheslav R Akmaev; Rangaprasad Sarangarajan; Chas Bountra; Stephen J Freedland; David G McLeod; Niven R Narain
Journal:  Sci Rep       Date:  2021-07-23       Impact factor: 4.379

9.  A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study.

Authors:  Mikio Sugimoto; Yoshiyuki Kakehi; Shigeo Horie; Yoshihiko Hirao; Hideyuki Akaza
Journal:  Jpn J Clin Oncol       Date:  2022-02-05       Impact factor: 3.019

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.